Alnylam Pharmaceuticals Inc reported strong financial results for Q4 2024, with revenues reaching $593.17 million, a year-over-year increase of 34.90% and a quarter-over-quarter increase of 18.42%. This growth is primarily attributed to robust sales of its RNAi therapeutics, especially ONPATTRO, GIVLAARI, and OXLUMO. Despite the impressive revenue growth, the company faced a net loss of $83.76 million and sustained significant operational expenses, particularly in research and development totaling approximately $300.17 million, emphasizing ongoing investment in its innovative pipeline.
Management reiterated their commitment to clinical advancement and market expansion during the earnings call, citing increased demand for their genetic therapies. However, the substantial increase in operational costs and persistent negative cash flow resulted in a precarious balance sheet, raising concerns about sustainability amidst ongoing cash burn. Investors need to monitor the interplay between revenue growth and operational efficiency closely.